Characteristics of Lynch syndrome associated ovarian cancer.

  title={Characteristics of Lynch syndrome associated ovarian cancer.},
  author={Jorien M. Woolderink and Geertruida H. de Bock and Joanne A de Hullu and H. Hollema and Ronald P Zweemer and Brigitte F. M. Slangen and Katja N Gaarenstroom and Marc van Beurden and H. C. van Doorn and Rolf H. Sijmons and Hans F A Vasen and Marian J. E. Mourits},
  journal={Gynecologic oncology},
  volume={150 2},

Figures and Tables from this paper

Serous ovarian carcinoma in patients with Lynch syndrome: Caution is warranted

Gynecological Cancers in Lynch Syndrome: A Comparison of the Histological Features with Sporadic Cases of the General Population

LS-associated EC and OC seem to have peculiar features, occurring at a younger age and at an earlier stage, compared with sporadic cancer cases.

Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer

The prevalence, prognosis and subsequent primary cancer incidence of patients with LS-associated EC in relation to sporadic mismatch repair deficient (MMRd)-EC in the large combined PORTEC-1,2 and -3 trial cohort was established.

Challenges in Managing Patients with Hereditary Cancer at Gynecological Services

To reveal current problems and challenges faced by the gynecologic services department in managing patients with hereditary cancers, positive or false-positive ascites cytology discovered during RRSO, and desired preservation of fertility is highly challenging.

The clinical features and management of Lynch syndrome‐associated ovarian cancer

This review thoroughly summarizes the current clinical evidence of surveillance, screening, and prevention strategies, and describes the molecular and clinical characteristics of LS‐associated OC.

Molecular pathology of Lynch syndrome

It is shown that the processes of autoimmunisation and immunoediting fundamentally constrain the development of tumours in LS and explain the efficacy of immune checkpoint blockade therapy in MMR‐deficient tumours.

Gynecological Surveillance and Surgery Outcomes in Dutch Lynch Syndrome Carriers

Although most surveillance visits happened within an advised timeframe, there was large variability in how gynecological surveillance visits were performed, stressing the need for development of clear and evidence-based guidelines.

BRCA-guided therapy of ovarian cancer

The incorporation of BRCA-targeted therapies, such as poly ADP ribose polymerase (PARP) inhibitors in the treatment algorithm of advanced EOC has further improved outcomes and represents a successful strategy of individualization of treatment in EOC.

Mainstreaming Genetic Testing for Epithelial Ovarian Cancer by Oncology Providers: A Survey of Current Practice

Investigation of the current genetic testing practices of oncology providers suggests that oncologist-led genetic testing for patients with EOC, with referrals to genetics professionals when appropriate, has the potential to be a viable alternative service delivery model to increase access.



Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors.

The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer.

HNPCC patients with ovarian cancer are more likely to have a synchronous endometrial cancer than other ovarian cancer patients and are morelikely to be diagnosed at an early stage, compared with the general population.

Distinct molecular profiles in Lynch syndrome‐associated and sporadic ovarian carcinomas

The significant molecular differences observed between LS‐associated and sporadic ovarian carcinomas help explain the different behavior of these tumors and emphasize the need for tailored clinical management.

Molecular, Pathologic, and Clinical Features of Early-Onset Endometrial Cancer: Identifying Presumptive Lynch Syndrome Patients

A risk of this magnitude would argue for routine immunohistochemical testing of tumors in patients diagnosed with EC at or before the age of 50 years, and to identify molecular, clinical, and pathologic features that may alert clinicians to the presence of this disorder.

Ovarian Endometrioid Adenocarcinoma: Incidence and Clinical Significance of the Morphologic and Immunohistochemical Markers of Mismatch Repair Protein Defects and Tumor Microsatellite Instability

In patients with ovarian endometrioid adenocarcinoma who undergo uterus-sparing surgery, abnormal MMR/MSI should prompt further diagnostic evaluation of the endometrium for tumor, as it did predict the involvement of the uterus by the tumor.

Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers

Annual surveillance, by transvaginal ultrasound scanning and serum CA125 measurement, in women at increased familial risk of ovarian cancer is ineffective in detecting tumours at a sufficiently early stage to influence substantially survival in BRCA1/2 carriers.

The risk of extra‐colonic, extra‐endometrial cancer in the Lynch syndrome

Urologic tract cancer and ovarian cancer occur frequently enough in some LS subgroups to justify trials to evaluate promising prevention interventions, and other cancer types studied occur too infrequently to justify strenuous cancer control interventions.

Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry

Findings confirm a clear dichotomy of uterine, ovarian and fallopian tube cancers associated with inheritance of mutations in BRCA1 and BRCa2 contrasted with Inheriting MMR gene mutations and opens possibilities for new approaches to molecular genetic research into carcinogenic pathways.

Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds

In the series examined, infiltrating ovarian cancer in Lynch syndrome had a better prognosis than infiltrating Ovarian cancer in BRCA1/2 mutation carriers or in the general population.